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n sub-Saharan Africa, almost 
60% of HIV infections are among 
women [1], and the number 
of new HIV infections in women 
worldwide continues to escalate. 
The high incidence of HIV in many 
African countries provides the 
optimum environment for research on 
technologies that could prevent women 
from becoming infected, including 
microbicides. In this article, we discuss 
the recent highly publicised closure of 
a trial of cellulose sulphate (CS), which 
we conducted. We discuss the impact 
of the closure on the participants, the 
community at the trial site and the 
public at large, the public health sector, 
national regulatory bodies, the media, 
and on other ongoing microbicide 
trials. The local lessons that we 
learnt from the closure may provide 
guiding principles for researchers 
and advocates in the HIV prevention 
ﬁ  eld as a whole, who may face similar 
situations in the future.
Previous Microbicide Trials
Vaginal microbicides are products 
which, when applied to the vagina, 
may prevent HIV transmission. Such a 
product would be particularly valuable 
for women who are unable to negotiate 
condom use with their partners, 
since its use would be initiated by 
the woman. The concept of a vaginal 
microbicide was tested several years ago 
using an over-the-counter spermicide, 
nonoxynol-9, a surfactant that acts by 
disrupting cell membranes. The trial, 
conducted in several African countries, 
showed an increase in risk of HIV 
among women who used the product 
more than three times a day [2].
The trial outcome was a huge setback 
for the microbicide ﬁ  eld. Nevertheless, 
almost a decade later, there are several 
products in large-scale clinical trials. 
These products were developed as a 
result of a better understanding of HIV-
1 pathogenesis, including identiﬁ  cation 
of HIV target cells [3].
In 2006, there was another 
disappointment with the stoppage of 
two trials of C31G (known as SAVVY), 
an antimicrobial and spermicidal 
agent. The trials were stopped because 
the HIV incidence was lower than 
expected in the target population, and 
it was unlikely that the trials would be 
able to show efﬁ  cacy against HIV [4]. 
There were no safety concerns with the 
product.
Of the current products in large-scale 
effectiveness trials, almost all belong 
to a class of compounds called fusion 
inhibitors. These act by preventing the 
virus from attaching to the target cells 
in the vagina. The current generation 
of products has poor speciﬁ  city to HIV. 
Two have contraceptive properties, 
three (BufferGel, Carraguard, and 
PRO 2000) have displayed in vitro 
evidence of inhibition of other sexually 
transmitted infections, and all of 
them are coitally dependent—that is, 
they must be used just prior to sexual 
intercourse [5].
Until recently there were ﬁ  ve 
products in large-scale phase IIb/III 
trials [6]: cellulose sulphate (Polydex 
Pharmaceuticals; http://www.polydex.
com/) [7–11], PRO 2000 0.5% 
and 2% (Indevus Pharmaceuticals; 
http://www.indevus.com/) [12], 
Carraguard (Population Council; 
http://www.popcouncil.org/)[13,14], 
and BufferGel (ReProtect; http://
www.reprotect.com/) [15]. Clinical 
trials of BufferGel and PRO 2000 
are still ongoing in several parts of 
Africa (Figure 1). A clinical trial of 
Carraguard was completed in March 
2007, and data analysis is in process. 
All ongoing clinical trials are reviewed 
regularly for safety by an external 
committee of experts—the data safety 
and monitoring committee (DSMC).
Closure of the CS Trial
In early 2007, there was another huge 
disappointment. The randomised 
controlled trial testing 6% cellulose 
sulphate against a placebo gel 
for effectiveness against vaginal 
transmission of HIV, sponsored by 
the reproductive health research 
organisation CONRAD (http://www.
conrad.org/), was stopped following 
recommendations by the DSMC after 
preliminary data review of 1,333 
enrolled women from ﬁ  ve sites (South 
Africa, Uganda, Benin, and two sites in 
India) suggested that there were more 
HIV seroconversions in the cellulose 
sulphate arm compared to the placebo 
arm of the trial. This unexpected 
outcome was a huge blow to the 
microbicide ﬁ  eld as CS, a non-cyclic 
antimicrobial agent, had been tested in 
several safety trials previously and there 
were no concerns about safety based on 
these trials [16].
The study DMSC was requested to 
provide guidance to the investigators 
if data indicated a difference of p < 
0.10 for futility or harm. At the ﬁ  rst 
review of 1,333 women in late January 
2007, there were 35 seroconversions 
from the three African sites, with a 
higher number of HIV seroconversions 
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in the CS arm compared to the 
placebo arm. The interim data analysis 
suggested that the boundary for safety 
had been crossed, and so the DMSC 
recommended stopping the trial to 
ensure the safety of the participants 
[17]. Data analysis is still ongoing to 
ascertain the reasons why the product 
was found to be potentially harmful. 
Another trial of the same product 
at two sites in Nigeria did not show 
the same effect but was also stopped 
as a precautionary measure for the 
participants’ safety [18].
Investigators at all sites were 
informed by CONRAD on 29 January 
2007 of the trial closure and a press 
release was planned for 31 January 
2007 [12]. The key message of the press 
release was that the trial was stopped 
because it was found that CS could lead 
to an increased risk of HIV.
Actions, Challenges, and 
Responses to the Trial Closure
The HIV Prevention Research 
Unit (HPRU) of the Medical 
Research Council (MRC) in South 
Africa participates in all ongoing 
microbicide trials. Prior to the 
release of the press statement by 
CONRAD, we immediately developed 
a communication strategy to ensure 
that the information to stakeholders 
came from the local researchers (Table 
1 and 2). Two days before the press 
release, we sent letters to the national 
and provincial departments of health, 
to the Medicines Control Council, 
which is South Africa’s drug regulatory 
authority, and to the ethics committee 
that had approved the trial, informing 
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Figure 1. Global Phase IIb/III Microbicide Clinical Trials
Red circle: Carraguard. Sponsored by Population Council. Phase III study of the efﬁ  cacy and safety of the microbicide Carraguard in preventing 
HIV seroconversion in women.
Blue cross: 2% and 0.5% PRO2000. Sponsored by Microbicide Development Programme. A phase III, multi-centre, randomised, double-
blind, placebo-controlled trial to evaluate the effectiveness and safety of 0.5% PRO2000 and 2% PRO2000 gels for the prevention of vaginally 
acquired HIV infection.
Yellow cross: BufferGel and 0.5% PRO2000. Sponsored by US National Institutes of Health. HPTN 035: Phase II/IIb safety and effectiveness 
study of the vaginal microbicides BufferGel and 0.5% PRO 2000 gel (P) for the prevention of HIV infection in women.
Green star: Cellulose sulphate—East and Southern Africa. Sponsored by CONRAD. Randomised controlled trial of 6% cellulose sulphate gel 
and the effect on vaginal HIV transmission.
Green star: Cellulose sulphate—Nigeria. Sponsored by Family Health International. Phase III trial of cellulose sulphate for HIV prevention.
Pink box: C31G (SAVVY). Sponsored by Family Health International. Phase III trial of SAVVY in Ghana and Nigeria.PLoS Medicine  |  www.plosmedicine.org 1169
them of the trial closure with a request 
for an urgent meeting.
We also sent letters to all community 
partners advising them that there were 
new developments in microbicide 
research, and requested community 
meetings at local levels. These 
letters did not provide details of the 
outcome of the trial as we felt it was 
better to give these details in a larger 
community meeting. We made contact 
with non-governmental organisations, 
advocacy groups (such as the Gender 
AIDS Forum; see http://www.gaf.
org.za/), women’s groups, and, most 
importantly, the research participants 
of the CS trial itself (Table 1 and 2). 
Community outreach staff encouraged 
all participants to use the toll-free 
telephone numbers set up at all HPRU 
research sites for any questions and 
concerns. The vaginal gel (CS or 
placebo) was collected within one week 
from 80% of the women in the trial. 
Currently, 95% of the women have 
been successfully notiﬁ  ed.
We contacted a journalist who writes 
regularly about HIV/AIDS issues, and 
asked her to write an article in a local 
newspaper providing information on 
the trial and reasons for its closure to 
avoid potential sensationalist reporting.
Negative Press
Despite these proactive steps to inform 
the wider community, some reporters 
wrote inaccurate and sensational 
stories. For example, on 4 February 
2007, a national weekly newspaper ran 
stories with the headlines “Medical 
research trial guinea pigs contract 
HIV” [19] and “Study to prevent 
AIDS left me infected”. These reports 
included sensational statements such 
as “Hundreds of women in South 
Africa, Benin, Nigeria, Uganda and 
India, who are being used as human 
guinea pigs in the US-funded research 
on HIV prevention, are feared to have 
contracted the virus during the course 
of the trials” [19]. In fact there were 
35 sero-incident cases among 1,333 
participants across all the African trial 
sites. This alarmist statement instilled 
fear amongst all trial participants. 
Statements in the article saying, for 
example, that women felt “used and 
misled” [19] falsely implied that the 
conduct of the study was unethical.
Subsequently, these sensational 
articles led to many spin-off articles 
in other local and national papers, 
including local language newspapers 
(Table 3). News stations were confused 
by the messages in these articles, and 
we were interviewed by several radio 
and television stations in order to 
clarify the concerns.
The national Department of 
Health (DOH) requested a meeting 
with us to discuss the trial closure. 
Following this meeting, the minister 
of health, in consultation with her 
advisory committee, issued a press 
statement with the key message that all 
microbicide trials in South Africa would 
be investigated for ethical conduct 
[20]. This was the correct stance to 
take given the volatile situation, and 
we welcomed investigation of the trial 
conduct [21]. However, we believe it 
would have been an ideal opportunity 
to inform the larger population of the 
stringent and world-class ethical and 
regulatory standards that govern South 
African clinical trials. We believe that 
the DOH could have given a more 
balanced view of the situation. Such a 
view would have acknowledged that: 
(1) the DOH is well informed of all 
clinical trials undertaken in the country 
through its clinical trial registry; 
(2) South Africa has national good 
clinical practice guidelines that must 
be followed for clinical trials; (3) all 
microbicide trials were conducted after 
thorough review of the protocols by 
ethics committees and drug regulatory 
authorities, with the latter governed 
by the DOH; and (4) these trials 
are regularly monitored by external 
reviewers. 
Similar meetings on trial conduct 
were held with the local KwaZulu-Natal 
DOH and the Parliamentary Health 
Portfolio Committee, a parliamentary 
subcommittee of members of 
parliament tasked to address health 
issues.
Impact upon Ongoing Microbicide 
Trials
Given that HPRU is involved in many 
clinical trials, the challenge was not 
only to address the closure of the CS 
trial, but to address the concerns of 
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Table 1. Key Dates
26 January 07 ß  DSMC meeting, Washington, D. C., US—decision made to halt study at all trial 
sites
28 January 07 ß  Director and PI informed of DSMC decision
30 January 07 ß  Director and PI instruct site to halt study and recall gel
ß  Standard messages developed 
31 January 07 ß  CONRAD press release
ß  Local press release
4 February 07 ß  Negative press article
7 February 07 ß  Health Minister releases press statement
ß  MRC President issues press statement in response to Health Minister’s statement
doi:10.1371/journal.pmed.0040235.t001
Table 2. Communication with Regulatory Authorities, Participants, and 
Community Stakeholders
Stakeholder Communication Dates
Regulatory Authorities
Ethics committee 30, 31 January 07; 13 February 07
Medicines Control Council  30, 31 January 07
National Department of Health 30 January 07; 2, 6, 7, 8 February 07
Provincial Department of Health 30, 31 January 07; 2, 7, 9, 14, 21, 27 February 07
Parliamentary Health Portfolio Committee 20 February 07
Participants and Community Stakeholders
Cellulose sulphate trial participants 30 January 07; ongoing
Other microbicide trial participants 30 January 07; ongoing
Peer educators 12, 15 February 07; ongoing
Community stakeholders (political and traditional) 5–9, 11–14, 16, 26, 27 February 07; 16 March 07; 
ongoing
Microbicide Trial Sponsors and Investigators
Microbicide trial sponsors 30 January 07
South African microbicide trial researchers  7 February 07
doi:10.1371/journal.pmed.0040235.t002PLoS Medicine  |  www.plosmedicine.org 1170
communities at trial sites of other 
ongoing microbicide trials in KwaZulu-
Natal.
We had several meetings with 
political ward councillors, research 
communities, and other concerned 
stakeholders (Table 2). Communities 
misinterpreted the minister of health’s 
press release, wrongly believing that 
the minister had called for all gel 
(microbicide) trials to be stopped 
(she had not—she had launched an 
investigation of the conduct of all 
microbicide trials). There were many 
irate people demanding answers to 
the following questions: (1) “Is it 
not unethical for researchers to ask 
innocent women to sleep with HIV-
positive men so that we can test to see 
if the gel works?”; 2) “Is it true that 
gel increased the risk of HIV infection 
among innocent women?”; 3) “Why did 
researchers expose poor black women 
to the infected gel?”; and 4) “How 
did researchers explain the study to 
illiterate women?”
Clinical trial investigators in South 
Africa are required by the Medicines 
Control Council to reimburse trial 
participants with a minimum of R150 
for trial participation to cover time, 
travel, and refreshments. But the 
general public’s perception was that 
women were “bought to sleep with 
HIV-positive men”. Many people 
believed that the gel contained 
HIV or that simply inserting the gel 
increased the risk of HIV infection 
irrespective of the sexual act. Responses 
from trial participants such as “you 
infected us with HIV” gave credence 
to these misconceptions. Although 
the community entry, approval, 
and educational process of clinical 
trials was thorough at the start of all 
trials, there was confusion as many 
communities doubted the information 
given to them at the outset prior to 
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Table 3. Communication with Media
Date Action Outcome
31 January 07 ß  Researchers invite local journalist to write article on CS trial closure immediately 
following CONRAD press statement
ß  CONRAD press statement released
ß  MRC press statement released
ß  Accurate reporting of study closure
1 February 07 ß  Above article printed in Durban daily newspaper
ß  PI interviewed by variety of local and national print, television, and radio media
ß  Other microbicide trial sponsors release press statements
2 February 07 ß  PI meets with national weekly newspaper journalist to give accurate information 
regarding clinical trials, informed consent, and the CS study closure
4 February 07 ß  National newspaper publishes articles referring to participants as “guinea pigs” 
and fuelling misperception that researchers encouraged participants to have 
unprotected sex with HIV-positive men [19]
ß  Numerous spin-off articles and electronic media reports
ß  Confusion amongst regulatory authorities, stakeholders, 
community, and participants
5 February  07 ß  Participants report that local language radio stations are warning all participants to 
stop using the gel and to stay away from MRC clinics
ß  Similar reports received from Microbicides Development Programme group at Africa 
Centre
ß  MRC media ofﬁ  cers contact all local radio stations to obtain air time to clarify 
inaccuracies
ß  Director does live television interview
ß  Negative articles sent to CONRAD and other microbicide trial sponsors
ß  1st draft of letter in response to 4 February article from CONRAD
ß  Live and recorded interviews aired on 5 radio stations 
clarifying misperceptions resulting from negative press 
messages
6 February 07 ß  Negative articles in local language daily newspaper appear on 6, 7, and 8 February ß  MRC sends letter to editor to clarify inaccuracies
7 February 07 ß  PI interviewed on television news report following Health Minister’s statement; ﬁ  rst 
positive messages emerge
ß  Community liaison ofﬁ  cer phones into live radio call-in programme to clarify 
negative messages
ß  Treatment Action Campaign issues positive statement on microbicide trials
ß  Positive messages dispel misperceptions created by 
negative press 
11 February 07 ß  National weekly newspaper publishes 2nd article
ß  CONRAD letter in response to 4 February article published
ß  Positive opinion piece from AIDS Law Project and renowned AIDS doctor published 
in same newspaper
ß  1st draft of MRC staff response to 4 February article
12 February 07 ß  MRC staff member sends letter to editor in response to 4 February article ß  Letter dispels inaccuracies
13–15 February 07 ß  MRC media ofﬁ  cers and CONRAD spokesperson meet with key journalists in Durban
ß  MRC develops strategy in response to press articles
ß  MRC research participants express unhappiness over misrepresentation in media 
and draft response to media
ß  Media achieves better understanding of clinical trials 
ß  Media expresses need for more information on continuing 
basis about microbicides and microbicide trials
ß  Participants express unhappiness over misrepresentation 
in the press
18 February 07 ß  MRC staff member letter to editor published (edited version) ß Letter  clariﬁ  es inaccuracies
doi:10.1371/journal.pmed.0040235.t003PLoS Medicine  |  www.plosmedicine.org 1171
trial implementation. Furthermore, 
some people expressed concern about 
the racial demographics of the trial 
participants, believing that we had 
“targeted” rural, poor, uneducated, and 
vulnerable women. The CS trial was 
in fact conducted at an urban site in 
Durban.
Impact on Study Participants
Participants from all other microbicide 
trials were affected by closure of the 
CS trial. Male partners who knew 
about women’s participation in other 
trials raised concerns that using “gel” 
increased HIV risk and did not want 
their female partners to participate 
in the trial. However, most women 
eventually decided to continue once 
they and their partners were counselled.
Peer educators in the community, 
who are also trial participants, were 
angry that the media described them 
as “poor”, “vulnerable”, “uneducated”, 
and “guinea pigs”. Women requested 
the researchers to link them to 
the media and the journalists who 
published inaccurate information so 
that they could voice their concerns. 
Most of the CS trial participants 
did not feel that trial participation 
increased their risk for HIV infection. 
They valued the beneﬁ  t of being 
in the study. Less than ten of the 
CS trial participants believed the 
information in the press articles and 
were understandably upset. All except 
two participants agreed to speak and 
listen to staff, who allayed participants’ 
fears. Two irate participants came 
to the clinic to return their gel and 
accused the researchers of trying to 
infect them with HIV. The partner of 
one participant burnt her gel supplies. 
Three participants and their partners 
attended the clinic for counselling.
Lessons Learnt
The outcome of the nonoxynol-9 
trial in 2000 was a huge setback for 
microbicide research in South Africa. 
Health authorities, ethics committees, 
and drug regulators were concerned 
about the safety of microbicides. 
Although the nonoxynol-9 trial 
received negative press, it was not as 
damaging at the community level as the 
closure of the CS trial, perhaps due to 
higher awareness now of microbicide 
clinical trials in South Africa as a whole. 
Furthermore, the 2006 closure of the 
SAVVY trial did not have an impact 
on current trials, possibly because the 
closure was not safety-related.
We learned several lessons from the 
closure of the CS trial that will provide 
us with a better understanding of 
communication strategies that may be 
required in many developing countries 
to deal with such situations in the future 
if they arise. Our recommendations for 
communicating about HIV prevention 
trials are shown in Box 1.
The ﬁ  rst lesson we learned is that 
the phrasing of the CONRAD press 
release was open for misinterpretation 
by the lay public. Due to regulatory 
requirements of publicly traded 
companies such as Polydex 
Pharmaceuticals, which developed 
the CS microbicide, it was impossible 
for CONRAD to ensure that all sites 
were included in drafting the press 
release. We suggest that sponsors and 
in-country investigators be proactive 
and prepare communication strategies 
based on all possible outcomes of 
DSMC reviews whether they be 
positive, negative, or no effect. We 
also recommend that these potential 
messages be developed in consultation 
with local researchers, community 
advisory boards, or community 
representatives. Such advice from 
the community on shaping messages 
would help to reduce the risk of facts 
being distorted, and would help deliver 
the messages in a manner which 
is appropriate to the community’s 
knowledge and understanding.
It is important that local health 
regulators such as the department of 
health and other governing bodies be 
kept informed on every aspect of the 
trial. Although regular updates were 
sent to the department, the frequency 
of updates was clearly not sufﬁ  cient 
especially regarding negative outcomes 
of clinical trials. Quarterly meetings 
would ensure that the department is 
kept informed of all aspects of ongoing 
clinical trials. It is imperative that 
trial outcomes are reported to the 
department by local investigators prior 
to media release.
Similarly, the ethical review of 
clinical trials needs to be strengthened. 
Currently regulatory bodies approve 
clinical trials, but site reviews on the 
conduct of trials are limited, primarily 
due to lack of human capacity. It is 
important to boost the capacity of local 
ethics committees and other regulatory 
bodies to ensure that once the trials 
are approved, the sites are reviewed 
regularly so that there are no doubts 
created about trial conduct when there 
are unexpected trial outcomes.
For principal investigators (PIs), 
our experience provides a valuable 
lesson on the importance of ensuring 
involvement of communities in 
all aspects of research, including 
disseminating messages about clinical 
trial outcomes. Communities and 
participants should be kept updated on 
not only the trial in their community, 
but on outcomes of trials of other 
prevention technologies. Such open 
and transparent communication will 
improve the community’s conﬁ  dence 
in the researchers.
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•  Emphasise community education.
•  Explain and emphasise to the 
community that HIV seroconversion is 
the only way to measure effectiveness 
of new prevention technologies 
including microbicides (i.e., there are 
no surrogate markers of infection that 
can be used in trials).
•  Educate the media and community 
about clinical trials, including 
regulatory procedures and good 
clinical practice guidelines followed by 
clinical trialists.
•  Develop early drafts of press 
releases of all possible DSMC 
outcomes—positive, negative, 
and no effect—in partnership with 
local researchers and community 
representatives.
•  Inform local ethics committees, drug 
regulatory authorities, and health 
authorities of trial outcome prior to 
press release.
•  In drafting press releases, be sure to 
include the contribution of in-country 
investigators, community advisory 
boards, and other relevant bodies.
•  Issue the press release in developing 
countries where the research is 
conducted. At the press conference, it 
is valuable to include the local principal 
investigator and representatives of the 
trial sponsor, ethics committee, and 
the local health authority.
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Fact sheets for communities need to 
be developed urgently once outcomes 
of prevention technologies are known. 
We have learnt that in addition to 
informing participant communities of 
the trial conducted in their community, 
it is important for us to provide them 
with an understanding of clinical trials 
in general. They need to understand 
that new drugs and interventions can 
only be introduced if the country’s 
regulatory authority is convinced by 
the evidence of the quality, safety, and 
efﬁ  cacy of the new product, and that 
such evidence can only come from 
clinical trials. They need to understand 
that clinical trials are particularly 
important if the product is designed 
for use by healthy individuals over a 
prolonged period of time, and that 
trials should preferably be conducted 
in communities that will use the 
product in case there are unforeseen 
pharmacogenetic interactions.
Perhaps the most important lesson 
learnt was that there is a need to educate 
the media on clinical trials as well as on 
the regulatory procedures and good 
clinical practice guidelines followed by 
clinical trialists. Despite our attempts to 
ensure that correct facts were published, 
the public was more attracted by 
sensational press articles. In most cases 
the media are hungry for news that will 
make headlines irrespective of whether 
the news is accurate or not. We suggest 
that sponsors and researchers set up 
media education sessions for each of the 
trials prior to implementation but also 
prior to results being released so that 
journalists have a good understanding 
of the outcomes of clinical trials and 
interpretation of data.
Since it is likely that most HIV 
prevention efﬁ  cacy trials will be 
conducted in developing countries 
with high HIV incidence, we believe 
that the ﬁ  rst press conference on 
a trial’s results should be held in 
participating countries with the 
presence of the national principal 
investigator, a representative of the 
study’s sponsor, and representatives 
from the local department of health 
and ethics committee. The in-country 
media would have the opportunity 
to direct any questions, concerns, or 
points of clariﬁ  cation to the principal 
investigator and sponsor rather than 
interpreting the results themselves. In 
our consultations with key journalists 
in Durban after the closure of the CS 
trial, they expressed the need to receive 
regular updates on microbicides and 
prevention research, rather than only 
receiving “bad” news about these trials.
One of the major challenges in 
HIV prevention research is that there 
are no surrogate markers for efﬁ  cacy. 
The only way to assess effectiveness 
of products is to measure new HIV 
infections as an outcome. It thus 
becomes extremely difﬁ  cult to make 
the lay public understand that in all 
prevention trials, participants are 
likely to become infected irrespective 
of the intervention, and it is not the 
researcher’s aim to increase infection or 
risk of infection. Prevention packages 
are provided to avoid infection, 
including safe sex counselling, 
provision of male and female condoms, 
treatment of sexually transmitted 
infections, and intense scrutiny of 
safety markers such as ulceration and 
abrasions in vaginal microbicide trials 
in particular. Although such packages 
may reduce HIV incidence overall, it 
is our ethical imperative to provide as 
much preventive advice as possible to 
reduce the rate of new HIV infections. 
One of the lessons here is to make 
the broader community understand 
more clearly that the only way we can 
test effectiveness of an HIV prevention 
technology is to assess the number of 
new HIV infections.
Conclusion
The closure of the CS trial has 
underscored the challenges we may 
face in the event of early trial closure 
due to a negative outcome. We now 
have insights on how to prepare for 
outcomes of future HIV prevention 
technologies and, at a minimum, 
prepare strategies to ensure that the 
messaging and process of message 
delivery is developed with local 
investigators, participant communities, 
local regulatory authorities, and in-
country media.
We believe that the lessons learnt 
here will provide guidance to the HIV 
prevention ﬁ  eld as a whole, as negative 
trial outcomes affect the future of HIV 
prevention research in the developing 
world.
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